Skip to main content
. Author manuscript; available in PMC: 2020 Apr 22.
Published in final edited form as: Gastroenterology. 2020 Jan 13;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006
4a. In adult outpatients with active moderate-severe ulcerative colitis, the AGA suggests using biologic monotherapy (TNFα antagonists, vedolizumab, ustekinumab) rather than thiopurine monotherapy for INDUCTION of remission. (Conditional recommendation, low quality evidence)
4b. In adult outpatients with moderate-severe ulcerative colitis in remission, the AGA makes no recommendation in favor of, or against, using biologic monotherapy (TNFα antagonists, vedolizumab or ustekinumab), rather than thiopurine monotherapy for MAINTENANCE of remission. (No recommendation, knowledge gap)